This document discusses different types of GMP inspections, including routine inspections, concise inspections, follow-up inspections, special inspections, and quality systems reviews. It provides details on the objectives and focus of each type of inspection. The frequency and duration of inspections depends on factors like the size of the company and the type of inspection. Inspections can be either announced or unannounced. Regulatory actions are taken based on national regulations and may include requiring correction of issues, closing a factory, or recalling products.
This document discusses the basic principles of good manufacturing practices (GMP) for materials used in pharmaceutical manufacturing. It covers requirements for different types of materials including starting materials, packaging materials, finished products, rejected materials, and more. Specific requirements addressed include purchasing, receiving, identification, storage conditions, dispensing, labeling, and control of these materials. Problems associated with materials are examined, along with how to properly manage materials to ensure quality and avoid issues.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
The document outlines guidelines for premises and equipment used in the production of traditional medicines and health supplements according to ASEAN standards. It discusses the design, construction, and maintenance of production areas, storage areas, and quality control areas to minimize risks of contamination and permit effective cleaning. Specific requirements for lighting, ventilation, flooring, drainage, and segregated material and personnel flow are provided. The document also addresses changing rooms and storage areas.
This document discusses different types of GMP inspections, including routine inspections, concise inspections, follow-up inspections, special inspections, and quality systems reviews. It provides details on the objectives and focus of each type of inspection. The frequency and duration of inspections depends on factors like the size of the company and the type of inspection. Inspections can be either announced or unannounced. Regulatory actions are taken based on national regulations and may include requiring correction of issues, closing a factory, or recalling products.
This document discusses the basic principles of good manufacturing practices (GMP) for materials used in pharmaceutical manufacturing. It covers requirements for different types of materials including starting materials, packaging materials, finished products, rejected materials, and more. Specific requirements addressed include purchasing, receiving, identification, storage conditions, dispensing, labeling, and control of these materials. Problems associated with materials are examined, along with how to properly manage materials to ensure quality and avoid issues.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
The document outlines guidelines for premises and equipment used in the production of traditional medicines and health supplements according to ASEAN standards. It discusses the design, construction, and maintenance of production areas, storage areas, and quality control areas to minimize risks of contamination and permit effective cleaning. Specific requirements for lighting, ventilation, flooring, drainage, and segregated material and personnel flow are provided. The document also addresses changing rooms and storage areas.
Labels must clearly identify containers, equipment, and premises. Labels provide information like the product name, batch number, status, and cleaning status. Documentation includes specifications for starting materials, packaging materials, finished products, and intermediates. Batch records document production and packaging. Standard operating procedures describe activities like equipment operation and cleaning, personnel matters, and sampling. Records of materials, production, packaging, equipment, and quality control must be kept for a defined period.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Line clearance is an important procedure to prevent mix-ups and mistakes during manufacturing. It involves three stages: clearing, cleaning, and checking. During clearing, materials from the previous production are removed. Next, cleaning is done according to standard operating procedures. Finally, the line is checked and any issues are recorded before clearance is given to begin the next production. Line clearance must be performed before various stages of production such as dispensing, filling, packaging, and more. It helps ensure safety and quality in manufacturing.
The document discusses the Master Formula Record (MFR), which contains all information about the manufacturing process for a pharmaceutical product. It is prepared by the research and development team and used as a reference standard for preparing batch manufacturing records. The MFR includes details like product name, ingredients, batch size, manufacturing process steps, packaging process, and expected yields. It provides standardized instructions for consistently producing batches of a product.
This document discusses guidelines for proper handling and control of materials used in pharmaceutical manufacturing according to WHO standards. It outlines requirements for various types of materials including starting materials, packaging, intermediates and bulk products, finished products, rejected materials, reference standards, and waste. Key requirements include quarantining materials after receipt, ensuring traceability through labeling and documentation, storing materials under appropriate conditions, and testing to release materials for use. The document also discusses procedures for recalled products and returned goods.
The document discusses documentation processes in organizations. It explains that documentation involves systematically recording people, events, and documents to create organizational records. Documentation provides information on how to complete tasks as well as evidence that tasks were done correctly. Master formula records (MFRs) are important documentation that contain all information about a pharmaceutical product's manufacturing process. MFRs are prepared by research teams and used as a reference for batch manufacturing records. The document outlines the key components that should be included in MFRs and batch manufacturing records to ensure consistency in manufacturing batches. It also discusses standard operating procedures and importance of documentation policies in organizations.
The document provides details on Master Formula Records (MFRs), including that MFRs:
- Are master documents that contain all information about manufacturing a pharmaceutical product, including ingredients, quantities, processes, and quality checks.
- Are prepared by the research and development team and used as a reference for batch manufacturing.
- Include product details, manufacturing processes, packaging processes, calculations, and quality approval by production and quality assurance heads.
MFRs ensure consistency in production and provide standards for Batch Manufacturing Records. Comprehensive information in MFRs allows for accurate reproduction of manufacturing batches.
This document provides an overview of production management for a seminar. It discusses production organization and how it is structured with roles like production planning, product design, production management, and quality assurance. It also covers material management aspects like material handling equipment, inventory management methods, and ABC analysis. The key points are:
1) Production management involves planning, implementing, and controlling industrial production processes to ensure smooth operations.
2) The production organization chart shows how roles like planning, design, management, and quality control are coordinated.
3) Material handling equipment includes conveyors, and inventory management methods aim to minimize costs and maintain supply-demand balance.
Staying Ahead of the Audit Curve with Food Industry Process AuditsAlchemy Systems
Process audits are a new approach to evaluating the effectiveness of your SQF System. They involve selecting a finished product lot and then auditing all the specific SQF components related to that lot. With SQFI considering adopting this methodology in SQF Code Edition 8, now is the time to learn about this process and start conducting your own internal process audits. Join this session to learn more about this process to test your system now and be ready for what’s coming soon!
Line clearance is a procedure to ensure equipment and work areas are free from materials from previous processes and ready for the next process. It involves clearing equipment of previous materials, cleaning, and checking. The purpose is to prevent mix-ups, contamination, and cross-contamination between products and batches. Proper line clearance, cleaning, separation of lines, and changeover approval are important cGMP requirements.
This is a practical session during vaccine and serum course. A course for the fourth year undergraduate students (Pharmacology domain) at department of virology, faculty of veterinary medicine, Cairo University.
This document discusses in-process quality assurance in pharmaceutical manufacturing. It defines quality as meeting consumer needs and outlines how quality is built into the manufacturing process through controls like following good manufacturing practices, input material control, process control, in-process checks, cross-checking, and product release controls. The document explains that in-process quality assurance is important to ensure products are consistently manufactured to quality standards by guiding operators about any deviations observed during production. It provides examples of in-process checks for various unit operations like blending, compression, and coating. The overall goal of in-process quality assurance is to reduce batch rejections and reprocessing by adopting controls that build quality into each stage of the manufacturing process.
This document outlines procedures for clearing and cleaning production lines before changing products to prevent mix-ups. It details:
- Removing all materials from the previous product, including documents. Supervisors ensure the area is cleared.
- Cleaning the area thoroughly once cleared. Two types of cleaning are described: batch-to-batch and product-to-product.
- Filling clearance documents and having QA personnel inspect and sign off before giving line clearance to proceed with the next product. Temperature, humidity and cleaning standards must be met.
Presentation: Cleaning and Contamination Control: A regulatory perspectiveTGA Australia
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
This document provides an overview of material management in the pharmaceutical industry. It discusses the various types of materials that must be managed, including raw materials, packaging materials, intermediates, finished products, rejected materials, and more. For each material type, it outlines the processes for purchasing, receiving, inspecting, storing, sampling, identifying, and dispatching the materials. Maintaining proper documentation and storage conditions at each stage is emphasized. The overall goal of pharmaceutical material management is to ensure the right quality and quantity of materials are obtained and handled correctly to enable the production of quality finished products.
Objectives and policies of cGMP & Inventory management and controlArul Packiadhas
This document discusses objectives and policies of CGMP (current good manufacturing practices) and inventory management and control. It outlines the importance of CGMP in assuring quality standards and preventing issues. CGMP regulations provide systems to properly design, monitor, and control manufacturing processes. The document also describes objectives of inventory control such as minimizing costs and ensuring adequate stock levels. It provides details on inventory management policies, documentation requirements, and quality control standards under CGMP.
The document summarizes key aspects of cGMP (current good manufacturing practices) and industrial management for pharmaceutical manufacturing. It discusses how cGMP regulations ensure drug quality and safety by establishing minimum requirements for facilities, equipment, and manufacturing processes. The document also outlines several important considerations for industrial management, including plant layout and organization, production planning and control, inventory management, quality management, and cost control. The overall goal is to integrate all functions for efficient and compliant pharmaceutical production.
This document discusses the importance of certifying vendors that supply raw materials for pharmaceutical manufacturing. Certification helps ensure high quality, safe medicines by preventing issues like contamination, recalls, deaths, and adverse events. It outlines six key steps in the vendor qualification process: 1) supplier selection, 2) due diligence, 3) quality assessment, 4) change control and production assessment, 5) supply chain security, and 6) ongoing monitoring and evaluation. Proper vendor certification and qualification of suppliers is necessary to maintain compliance and minimize risks to patients.
This document provides an overview of Good Manufacturing Practice (GMP) requirements for materials used in pharmaceutical manufacturing. It discusses specific requirements for different types of materials including starting materials, packaging materials, intermediates, finished products, and more. The objectives are to review GMP requirements for each material type and examine common problems associated with materials compliance. The document outlines general material controls such as supplier approval, material receipt checks, quarantine, storage conditions, labeling, and change control.
This document discusses documentation requirements for good manufacturing practices (GMP) according to WHO guidelines. It covers labeling requirements for containers, equipment, and premises. It also discusses specifications for starting materials, packaging materials, finished products, and intermediates. Master formulas and batch processing records are described. Standard operating procedures (SOPs) are discussed, including activities that require SOPs. Different types of records are outlined, including where they should be stored.
Labels must clearly identify containers, equipment, and premises. Labels provide information like the product name, batch number, status, and cleaning status. Documentation includes specifications for starting materials, packaging materials, finished products, and intermediates. Batch records document production and packaging. Standard operating procedures describe activities like equipment operation and cleaning, personnel matters, and sampling. Records of materials, production, packaging, equipment, and quality control must be kept for a defined period.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
Line clearance is an important procedure to prevent mix-ups and mistakes during manufacturing. It involves three stages: clearing, cleaning, and checking. During clearing, materials from the previous production are removed. Next, cleaning is done according to standard operating procedures. Finally, the line is checked and any issues are recorded before clearance is given to begin the next production. Line clearance must be performed before various stages of production such as dispensing, filling, packaging, and more. It helps ensure safety and quality in manufacturing.
The document discusses the Master Formula Record (MFR), which contains all information about the manufacturing process for a pharmaceutical product. It is prepared by the research and development team and used as a reference standard for preparing batch manufacturing records. The MFR includes details like product name, ingredients, batch size, manufacturing process steps, packaging process, and expected yields. It provides standardized instructions for consistently producing batches of a product.
This document discusses guidelines for proper handling and control of materials used in pharmaceutical manufacturing according to WHO standards. It outlines requirements for various types of materials including starting materials, packaging, intermediates and bulk products, finished products, rejected materials, reference standards, and waste. Key requirements include quarantining materials after receipt, ensuring traceability through labeling and documentation, storing materials under appropriate conditions, and testing to release materials for use. The document also discusses procedures for recalled products and returned goods.
The document discusses documentation processes in organizations. It explains that documentation involves systematically recording people, events, and documents to create organizational records. Documentation provides information on how to complete tasks as well as evidence that tasks were done correctly. Master formula records (MFRs) are important documentation that contain all information about a pharmaceutical product's manufacturing process. MFRs are prepared by research teams and used as a reference for batch manufacturing records. The document outlines the key components that should be included in MFRs and batch manufacturing records to ensure consistency in manufacturing batches. It also discusses standard operating procedures and importance of documentation policies in organizations.
The document provides details on Master Formula Records (MFRs), including that MFRs:
- Are master documents that contain all information about manufacturing a pharmaceutical product, including ingredients, quantities, processes, and quality checks.
- Are prepared by the research and development team and used as a reference for batch manufacturing.
- Include product details, manufacturing processes, packaging processes, calculations, and quality approval by production and quality assurance heads.
MFRs ensure consistency in production and provide standards for Batch Manufacturing Records. Comprehensive information in MFRs allows for accurate reproduction of manufacturing batches.
This document provides an overview of production management for a seminar. It discusses production organization and how it is structured with roles like production planning, product design, production management, and quality assurance. It also covers material management aspects like material handling equipment, inventory management methods, and ABC analysis. The key points are:
1) Production management involves planning, implementing, and controlling industrial production processes to ensure smooth operations.
2) The production organization chart shows how roles like planning, design, management, and quality control are coordinated.
3) Material handling equipment includes conveyors, and inventory management methods aim to minimize costs and maintain supply-demand balance.
Staying Ahead of the Audit Curve with Food Industry Process AuditsAlchemy Systems
Process audits are a new approach to evaluating the effectiveness of your SQF System. They involve selecting a finished product lot and then auditing all the specific SQF components related to that lot. With SQFI considering adopting this methodology in SQF Code Edition 8, now is the time to learn about this process and start conducting your own internal process audits. Join this session to learn more about this process to test your system now and be ready for what’s coming soon!
Line clearance is a procedure to ensure equipment and work areas are free from materials from previous processes and ready for the next process. It involves clearing equipment of previous materials, cleaning, and checking. The purpose is to prevent mix-ups, contamination, and cross-contamination between products and batches. Proper line clearance, cleaning, separation of lines, and changeover approval are important cGMP requirements.
This is a practical session during vaccine and serum course. A course for the fourth year undergraduate students (Pharmacology domain) at department of virology, faculty of veterinary medicine, Cairo University.
This document discusses in-process quality assurance in pharmaceutical manufacturing. It defines quality as meeting consumer needs and outlines how quality is built into the manufacturing process through controls like following good manufacturing practices, input material control, process control, in-process checks, cross-checking, and product release controls. The document explains that in-process quality assurance is important to ensure products are consistently manufactured to quality standards by guiding operators about any deviations observed during production. It provides examples of in-process checks for various unit operations like blending, compression, and coating. The overall goal of in-process quality assurance is to reduce batch rejections and reprocessing by adopting controls that build quality into each stage of the manufacturing process.
This document outlines procedures for clearing and cleaning production lines before changing products to prevent mix-ups. It details:
- Removing all materials from the previous product, including documents. Supervisors ensure the area is cleared.
- Cleaning the area thoroughly once cleared. Two types of cleaning are described: batch-to-batch and product-to-product.
- Filling clearance documents and having QA personnel inspect and sign off before giving line clearance to proceed with the next product. Temperature, humidity and cleaning standards must be met.
Presentation: Cleaning and Contamination Control: A regulatory perspectiveTGA Australia
The document discusses regulatory perspectives on cleaning and contamination control from an inspector of the Therapeutic Goods Administration in Australia. It covers current GMP requirements, future GMP developments, observed good practices in contamination control, and common deficiencies found in inspections. Some key points include that contamination control strategies should be risk-based and rely on quality risk management principles. Inspections often find deficiencies in assessing intrinsic hazards of products and processes, in the design of facilities and equipment to control contamination risks, and in validation of cleaning processes.
This document provides an overview of material management in the pharmaceutical industry. It discusses the various types of materials that must be managed, including raw materials, packaging materials, intermediates, finished products, rejected materials, and more. For each material type, it outlines the processes for purchasing, receiving, inspecting, storing, sampling, identifying, and dispatching the materials. Maintaining proper documentation and storage conditions at each stage is emphasized. The overall goal of pharmaceutical material management is to ensure the right quality and quantity of materials are obtained and handled correctly to enable the production of quality finished products.
Objectives and policies of cGMP & Inventory management and controlArul Packiadhas
This document discusses objectives and policies of CGMP (current good manufacturing practices) and inventory management and control. It outlines the importance of CGMP in assuring quality standards and preventing issues. CGMP regulations provide systems to properly design, monitor, and control manufacturing processes. The document also describes objectives of inventory control such as minimizing costs and ensuring adequate stock levels. It provides details on inventory management policies, documentation requirements, and quality control standards under CGMP.
The document summarizes key aspects of cGMP (current good manufacturing practices) and industrial management for pharmaceutical manufacturing. It discusses how cGMP regulations ensure drug quality and safety by establishing minimum requirements for facilities, equipment, and manufacturing processes. The document also outlines several important considerations for industrial management, including plant layout and organization, production planning and control, inventory management, quality management, and cost control. The overall goal is to integrate all functions for efficient and compliant pharmaceutical production.
This document discusses the importance of certifying vendors that supply raw materials for pharmaceutical manufacturing. Certification helps ensure high quality, safe medicines by preventing issues like contamination, recalls, deaths, and adverse events. It outlines six key steps in the vendor qualification process: 1) supplier selection, 2) due diligence, 3) quality assessment, 4) change control and production assessment, 5) supply chain security, and 6) ongoing monitoring and evaluation. Proper vendor certification and qualification of suppliers is necessary to maintain compliance and minimize risks to patients.
This document provides an overview of Good Manufacturing Practice (GMP) requirements for materials used in pharmaceutical manufacturing. It discusses specific requirements for different types of materials including starting materials, packaging materials, intermediates, finished products, and more. The objectives are to review GMP requirements for each material type and examine common problems associated with materials compliance. The document outlines general material controls such as supplier approval, material receipt checks, quarantine, storage conditions, labeling, and change control.
This document discusses documentation requirements for good manufacturing practices (GMP) according to WHO guidelines. It covers labeling requirements for containers, equipment, and premises. It also discusses specifications for starting materials, packaging materials, finished products, and intermediates. Master formulas and batch processing records are described. Standard operating procedures (SOPs) are discussed, including activities that require SOPs. Different types of records are outlined, including where they should be stored.
The document discusses material management in the pharmaceutical industry. It defines material management as the planning, organizing, and control of materials from initial purchase through their destination. The key functions of material management include purchasing, handling raw materials, packaging materials, intermediate and bulk products, finished products, rejected materials, recalled products, returned goods, and reagents. Maintaining proper documentation and quality control is important at each stage to ensure consistency and quality of pharmaceutical products.
This document discusses the basic principles of documentation in Good Manufacturing Practices (GMP). It outlines general documentation principles such as documentation defining specifications and procedures, ensuring all personnel know what to do, and providing an audit trail. Specific requirements covered include documents being designed, prepared, reviewed and distributed with care, complying with marketing authorization, and being approved, signed and dated. The document also discusses general principles for data entry, storage, and retention in documentation.
ANALYSIS OF RAW MATERIALS, FINISHED PRODUCTS, PACKAGING MATERIALS, IPQC, CPCS...Khadeeja6
RAW MATERIALS
It is basically the chemical ingredients of a process. starting material, in production of final product.
FINISHED PRODUCTS
Marketable product, transportable pack, salable pack
PACKAGING MATERIAL
Providing presentation, protection, identification, information, containment, convenience compliance, integrity and stability for a product during storage, transportation display and until it is consumed or throughout its shelf life.
IPQC
Providing accurate, specific and definite description of the procedures to be employed from the receipt of raw materials to the release of the finished dosage form.
CPCSEA GUIDELINES
Role of CPCSEA is to monitor animal experiments through ethics committees set up in institutions (IAEC)
CPCSEA Nominee -important link between CPCSEA and IAEC
IAEC scrutinize all project proposals for experimentation on animals.
The validity of IAEC is for 3 years.
MATERIAL MANAGEMENT QUALITY ASSURANCE TECHNIQUESalmanLatif14
The document discusses material management in the pharmaceutical industry. It covers various topics related to material management including definitions, objectives, purchasing, storage, and handling of raw materials, packaging materials, intermediates, rejected materials, and other item types. Proper documentation, labeling, storage conditions, and quality control are important for ensuring materials are suitable for use in manufacturing pharmaceutical products. The key goal of material management is to source high quality input materials and control their flow through the manufacturing process to deliver quality finished products on time.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
The document discusses quality management and good manufacturing practices (GMP) in the pharmaceutical industry. It defines quality management as determining and implementing quality policies through an appropriate quality system. GMP is described as ensuring products are consistently produced according to quality standards and marketing authorizations through defined processes and validated equipment and facilities. The key components of an effective GMP system include premises and equipment qualification, trained personnel, process and product testing, and documentation of manufacturing and distribution activities.
Tài liệu GMP được chia sẻ bởi GMPc Việt Nam - Nhà tư vấn Sáng tạo, Chuyên nghiệp, Toàn diện Dự án Nhà máy GMP (EU, PIC/S, WHO, ASEAN), ISO 13485:2012, ISO/IEC 17025:2005, ISO 15189:2012, ISO 15378:2011, ISO 9001:2008
This document provides an overview of general requirements for pharmaceutical manufacturing premises according to Good Manufacturing Practice (GMP) standards. It discusses location, design, construction, and maintenance of facilities. Specific areas covered include ancillary areas, storage areas, weighing rooms, production areas, and quality control laboratories. Key requirements addressed are preventing cross-contamination, permitting effective cleaning and maintenance, and controlling temperature, humidity and air quality. The document aims to help ensure premises are suitable for intended operations and manufacturing of quality products.
Raw materials include all materials used in manufacturing a finished product, whether present in the final product or not. They must meet defined purchase specifications. Key steps in purchasing raw materials include requisition, supplier selection, quotation, order placement, receipt, and payment. Proper storage conditions must be maintained based on product requirements. Vendors are selected and qualified to ensure a consistent supply of materials meeting quality standards. Receipt, storage, and sampling of materials are controlled through standard operating procedures.
Good Laboratory Practice (GLP) guidelines provide standards for laboratory experiments and tests performed to support research, nonclinical studies, and regulatory submissions. The key goals of GLP are to ensure quality, reliability, and integrity of data through adherence to standard operating procedures, trained personnel, appropriate facilities and equipment, records management, and quality control. GLP aims to promote valid and robust research that can be reproduced internationally and supports regulatory review and decision making.
This document discusses sanitation and hygiene principles for manufacturing facilities. It covers maintaining high standards of sanitation for personnel, premises, equipment, materials and products. Personal hygiene measures include health checks for employees, training on hygiene practices, prohibiting illness or lesions in production areas. The design of premises and production operations must facilitate effective cleaning and prevent contamination. Personnel hygiene procedures like protective clothing and handwashing apply to all persons in production areas. Group activities involve identifying sanitation issues in photographs and key hygiene considerations for a new factory.
Hold-time studies establish the maximum acceptable time periods that materials at different stages of production can be held before processing to the next stage while still meeting quality acceptance criteria. The studies involve collecting data from pilot batches, process validation, or investigations to justify hold times. Manufacturers map out critical stages and potential pauses on a flow chart and conduct testing at intervals on samples stored under appropriate conditions. Test results are compared to acceptance limits, which are more stringent than specifications, to confirm the material remains well within control during the defined hold period.
This document discusses principles of self-inspection and quality audits in pharmaceutical production. It covers objectives of self-inspection including identifying roles in quality management. Key areas to inspect include production procedures, equipment, materials handling, batch records, and deviations. Effective self-inspection requires defined teams, inspection programs, checklists, reports, and corrective action plans. External audits verify compliance and can include regulatory, contractor, or supplier audits. Auditors should evaluate self-inspection programs and ensure defined processes are followed.
This document discusses material management in the pharmaceutical industry. It defines material management as planning, organizing, and controlling the flow of materials from initial purchase through internal operations to distribution. It describes the various stages of material management including purchasing, receiving, storage, and handling of raw materials, packaging materials, intermediates, bulk products, finished products, rejected materials, recalled products, returned products, reagents, waste, and other miscellaneous materials. Proper documentation, labeling, testing, and storage conditions are important at each stage to ensure quality control.
This document provides an overview of qualification and validation principles according to Good Manufacturing Practices (GMP). It defines qualification and validation, and explains their scope, principles, types of documentation, and importance. Qualification and validation provide documented evidence that critical aspects of manufacturing are controlled. The document outlines the key elements that should be addressed in a validation master plan, protocol, and report. It also discusses new approaches to validation including risk assessment and a three-phase process design.
The special measures that need to be considered in the
storage and distribution of product, such that the
products will be of the nature and quality intended
when it reaches the consumer
Similar to Tiêu chuẩn GMP WHO: Nguyên liệu sản xuất (20)
This document provides guidance on good manufacturing practices for medicinal products. It discusses the importance of a pharmaceutical quality system to ensure that manufactured medicines are fit for use and comply with regulatory standards. Key elements of the quality system include good manufacturing practices, quality control, product quality reviews, and quality risk management. The quality system requires participation across all departments and levels of the company to ensure product safety, quality and efficacy.
This document discusses key aspects of designing pharmaceutical manufacturing facilities according to current Good Manufacturing Practices (cGMP). It covers process design tools like block flow diagrams, process flow diagrams, and piping and instrumentation diagrams that are used to design the facility layout and process flows. The document also discusses various unit operations in solid dosage manufacturing like material handling, milling, blending, compression, and coating. Facility design must meet regulatory requirements to facilitate operations, control materials, and prevent contamination according to cGMP.
This document lists various prequalified active pharmaceutical ingredients from the WHO. It includes the product ID, INN, grade, therapeutic area, applicant, date of prequalification, and confirmation date. There are over 400 entries listed with information about different APIs that have been prequalified for treatments of conditions like HIV/AIDS, malaria, tuberculosis, hepatitis, and others.
Danh mục 37 thuốc sản xuất trong nước được cấp giấy phép lưu hành tại Việt Nam - Đợt 185.
Quyết định được Cục Quản lý Dược Việt Nam ban hành vào tháng 7 năm 2023.
Danh mục 259 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 185.
Danh mục được ban hành bới Cục Quản lý Dược Việt Nam tháng 7 năm 2023.
Ngày 21/06 vừa qua, cục Quản lý Dược vừa ban hành quyết định về việc công bố danh mục thuốc biệt dược gốc - đợt 2 năm 2023.
Ban hành kèm theo quyết định này bao gồm 83 thuốc biệt dược gốc.
Xem thêm các tài liệu khác trên trang của công ty cổ phần Tư vấn thiết kế GMP-EU.
Hướng dẫn thực hành này cung cấp thông tin cho các nhà sản xuất thức ăn có chất sát khuẩn không an toàn do thuốc chuyển sang thức ăn chăn nuôi không chứa thuốc hoặc một loại thức ăn khác. Mục đích của hướng dẫn này:
• “Sản xuất và phân phối thức ăn có chứa thuốc” đề cập đến việc sử dụng thiết bị để sản xuất, chế biến, đóng gói, giữ và phân phối thức ăn.
• “Thức ăn chăn nuôi” được sản xuất có thêm hóa chất bảo quản. Thức ăn cho động vật như vậy có thể được gọi trong hướng dẫn này là “thức ăn có tẩm thuốc” hoặc “thức ăn không có tẩm thuốc”, tùy thuộc vào việc thức ăn đó có được pha chế để chứa một loại thuốc mới dành cho động vật hay không. Để thuận tiện, chúng tôi gọi những loại thuốc mới dành cho động vật này đơn giản là “thuốc”.
• “Thuốc mang theo” đề cập đến sự hiện diện của thuốc trong lô thức ăn chăn nuôi tiếp theo.
• “Ô nhiễm không an toàn”: đề cập đến mức độ nhiễm bẩn, do một loại thuốc được phép sử dụng trong thức ăn chăn nuôi, gây ra rủi ro không thể chấp nhận được đối với sức khỏe con người hoặc động vật.
Nói chung, các tài liệu hướng dẫn của FDA không thiết lập các trách nhiệm có thể thực thi về mặt pháp lý. Thay vào đó nó mô tả Cơ quan về một chủ đề và chỉ nên được xem dưới dạng khuyến nghị, trừ khi các yêu cầu pháp lý hoặc quy định cụ thể được trích dẫn. Việc sử dụng từ nên trong hướng dẫn của Cơ quan có nghĩa là điều gì đó được gợi ý hoặc khuyến nghị, nhưng không bắt buộc.
Xem thêm các tài liệu khác trên trang của công ty cổ phần tư vấn thiết kể GMP EU.
Cục Quản lý Thực phẩm và Dược phẩm Hoa Kỳ đưa ra hướng dẫn cho các nhà sản xuất và phân phối sữa cho trẻ sơ sinh về các yêu cầu ghi nhãn nhất định đối với các sản phẩm này. Hướng dẫn này đặc biệt chú trọng đến số lượng các công thức sữa cho trẻ sơ sinh có bao bì tương tự nhưng khác nhau về thành phần hoặc mục đích sử dụng. Ngày càng nhiều các sản phẩm ghi sai nhãn về hàm lượng chất dinh dưỡng, do vậy hướng dẫn này cung cấp thông tin có thể giúp các nhà sản xuất hiểu và tuân thủ các yêu cầu ghi nhãn liên quan.
Hướng dẫn này không bao gồm đầy đủ tất cả các quy định liên quan đến việc ghi nhãn sữa công thức dành cho trẻ sơ sinh. Vì vậy bạn có thể xem thêm các hướng dẫn khác tại www.fda.gov/FoodGuidances hoặc các tài liệu trên kênh của công ty cổ phần tư vấn thiết kế GMP EU.
Ngày 25/05 vừa qua, Cục quản lý Dược vừa ban hành danh mục 69 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 184.
Theo đó, ban hành kèm theo Quyết định này danh mục 69 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 184, cụ thể:
1. Danh mục 64 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam hiệu lực 05 năm (Phụ lục I kèm theo).
2. Danh mục 05 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam hiệu lực 03 năm (Phụ lục II kèm theo).
Xem thêm các tài liệu khác trên trang của công tư cổ phần tư vấn thiết kế GMP EU.
Ngày 25/05 vừa qua, Cục quản lý Dược đã ban hành quyết định số 352/QĐ-QLD về việc ban hành danh mục 231 thuốc nước ngoài được cấp, gia hạn giấy đăng ký lưu hành tại Việt Nam - Đợt 184.
Theo đề nghị của Trưởng phòng Đăng ký thuốc, Cục Quản lý Dược quyết định:
Ban hành kèm theo Quyết định này danh mục 231 thuốc sản xuất trong nước được cấp giấy đăng ký lưu hành tại Việt Nam - Đợt 184, cụ thể:
1. Danh mục 172 thuốc sản xuất trong nước được gia hạn giấy đăng ký lưu hành hiệu lực 05 năm (Phụ lục I kèm theo).
2. Danh mục 52 thuốc sản xuất trong nước được gia hạn giấy đăng ký lưu hành hiệu lực 03 năm (Phụ lục II kèm theo).
3. Danh mục 07 thuốc sản xuất trong nước được gia hạn đăng ký lưu hành đến 31/12/2025 (Phụ lục III kèm theo).
Xem thêm các tài liệu khác trên trang của công ty cổ phần Tư vấn thiết kế GMP EU.
Ngày 26/05 vừa qua, Cục Quản lý Dược đã ban hành quyết định số 371/QĐ-QLD về việc công bố danh mục thuốc biệt dược gốc Đợt 1 - năm 2023.
Theo đề nghị của Trưởng phòng Đăng ký thuốc - Cục Quản lý Dược, quyết định:
Công bố Danh mục 56 thuốc Biệt dược gốc Đợt 1 - Năm 2023 tại Phụ lục kèm theo Quyết định này.
Xem thêm các tài liệu khác trên trang của công ty cổ phần Tư vấn thiết kế GMP EU.
Ngày 26/05 vừa qua, Cục Quản lý Dược vừa ra quyết định số 370/QĐ-QLD về việc ban hành danh mục 50 thuốc nước ngoài được cấp, gia hạn giấy đăng ký lưu hành tại Việt Nam - Đợt 111 bổ sung.
Theo đề nghị của Trưởng phòng Đăng ký thuốc - Cục Quản lý Dược quyết định:
Ban hành kèm theo Quyết định này danh mục 50 thuốc nước ngoài được cấp, gia hạn giấy đăng ký lưu hành tại Việt Nam - Đợt 111 bổ sung, bao gồm:
1. Danh mục 41 thuốc nước ngoài được cấp giấy đăng ký lưu hành hiệu lực 05 năm - Đợt 111 bổ sung (tại Phụ lục I kèm theo).
2. Danh mục 01 thuốc nước ngoài được cấp giấy đăng ký lưu hành hiệu lực 03 năm - Đợt 111 bổ sung (tại Phụ lục II kèm theo).
3. Danh mục 07 thuốc nước ngoài được gia hạn giấy đăng ký lưu hành hiệu lực 05 năm - Đợt 111 bổ sung (tại Phụ lục III kèm theo).
4. Danh mục 01 thuốc nước ngoài được gia hạn giấy đăng ký lưu hành đến 31/12/2025 - Đợt 111 bổ sung (tại Phụ lục IV kèm theo).
Ngày 24/05 vừa qua, Bộ Y tế vừa ban hành quyết định về việc công bố danh mục thuốc có chứng minh tương đương sinh học đợt 2 - năm 2023.
Theo đề nghị của Trưởng phòng Đăng ký thuốc - Cục quản lý Dược, quyết định:
Công bố Danh mục 28 thuốc có chứng minh tương đương sinh học Đợt 2 - Năm 2023 tại Phụ lục kèm theo Quyết định này.
Xem thêm các tài liệu khác của Công ty cổ phần Tư vấn thiết kế GMP EU.
More from Công ty Cổ phần Tư vấn Thiết kế GMP EU (20)
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
Debunking Nutrition Myths: Separating Fact from Fiction"AlexandraDiaz101
In a world overflowing with diet trends and conflicting nutrition advice, it’s easy to get lost in misinformation. This article cuts through the noise to debunk common nutrition myths that may be sabotaging your health goals. From the truth about carbohydrates and fats to the real effects of sugar and artificial sweeteners, we break down what science actually says. Equip yourself with knowledge to make informed decisions about your diet, and learn how to navigate the complexities of modern nutrition with confidence. Say goodbye to food confusion and hello to a healthier you!
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
2. Materials
|
Module11 Slide2of25 2012
Objectives
To review specific requirements for each type of material:
Starting materials
Packaging materials
Intermediate and bulk products
Finished products
Rejected and recovered materials
Recalled products
Returned goods
Reagents and culture media
Reference standards
Waste materials
Miscellaneous materials
To examine (in groups) the problems associated with materials,
and how to overcome them
3. Materials
|
Module11 Slide3of25 2012
Principle
Objective of the pharmaceutical manufacturer
produce finished products for patient's use from a
combination of materials
Materials combined
Active pharmaceutical ingredients and
Excipients (auxiliary materials)
Packaging materials
Materials include also
Gases, solvents, reagents, process aids, etc.
Special attention 14.1, 14.2
4. 14.3–14.6
Materials
|
Module11 Slide4of25 2012
General requirements for materials
Materials for cleaning, lubrication, and pest control
Not in direct contact with product
Suitable grade, e.g. food grade if possible
All incoming materials and finished products
quarantined after receipt or processing
– until released for use or distribution
stored
– under appropriate conditions
– orderly fashion (batch segregation)
– materials management
– stock rotation (FEFO)
Water – suitable for use
5. 14.7 – 14.10
Materials
|
Module11 Slide5of25 2012
Starting Materials – I
Purchasing – important operation
From approved suppliers – if possible, direct from the producer
Specifications for materials
Consignment checks
Integrity of package
Seal intact
As per purchase order
Delivery note
Supplier’s labels
Clean containers and label – ensure information readable
6. 14.11 – 14.14
Materials
|
Module11 Slide6of25 2012
Starting Materials – II
Report damage to containers
Separate different batches in one delivery
– sampling, testing and release
Starting materials labelled
name and internal code
Supplier's batch number(s) and manufacturer's on receipt
Status (e.g. quarantine, on test, etc.)
expiry date or retest date
Role of validated computer system
7. Basic Principles of GMP
Damage to and problems
with containers
Recorded and reported
to QC
Investigated
|
Module11 Slide7of25 2012
8. Materials
|
Module11 Slide8of25 2012
Examples of Labelling of Starting Materials
Name of
Material and/or
internal code
Control/
Batch No.
Status
Quarantined/Released/Rejected
(Colours may be used)
Expiry date or
retest date
Date Signature
9. Basic Principles of GMP
Procedure for sampling followed - containers
labelled
|
Module11 Slide9of25 2012
10. 14.15 – 14.18
Materials
|
Module11 Slide10of25 2012
Starting Materials – III
Use only QC released material if within shelf-life
Dispensing
designated persons
written procedure
ensure that correct materials are accurately weighed
clean, properly labelled containers
Independent checks - recorded
material and weight or volume
Dispensed material kept together and labelled
12. 14.19 –14.20
Materials
|
Module11 Slide12of25 2012
Packaging materials - I
Primary and printed packaging materials
purchasing, handling and control same as for starting
materials
Printed packaging materials:
Stored in secure conditions with authorized access
Roll labels where possible in place of cut labels
Loose materials stored and transported in separate, closed
containers - to avoid mix-ups
Issued by designated personnel
SOP for issue and returns
14. 14.21 – 14.23
Materials
|
Module11 Slide14of25 2012
Printed and primary packaging materials - II
Each delivery or batch: specific reference number or
identification mark
Delivery to packaging department
Check quantity, identity and conformity to packaging
instructions
Outdated or obsolete material
Destroyed
Disposal record
15. Basic Principles of GMP
Intermediate and bulk
products
Kept under appropriate
conditions e.g. temperature
If purchased as such
Handled on receipt as
though these are
starting materials
14.24 – 14.25
|
Module11 Slide15of25 2012
16. Basic Principles of GMP
Finished products
Held in quarantine until their
final release
Then stored as usable stock
under suitable storage
conditions
Evaluation and
documentation necessary
for release
Product release procedure
Batch record review and
related procedure
14.26 – 14.27
|
Module11 Slide16of25 2012
17. 14.28
Materials
|
Module11 Slide17of25 2012
Rejected materials
Rejected materials and products
Clearly marked
Stored separately in restricted areas
Action – returned to supplier/destroyed, etc. in timely manner
Action approved by authorized personnel – records
maintained
18. 14.29 – 14.31
Materials
|
Module11 Slide18of25 2012
Rejected, reworked and recovered materials
Rework and recovery
Only in exceptional cases
– Risks involved have been evaluated and the quality of
final product will not be affected
– Specifications are met
– Defined procedure
– Records maintained
– New batch number
additional testing considered by QC
19. 14.32 – 14.33
Materials
|
Module11 Slide19of25 2012
Recalled products and returned goods
Recalled products
Identified
Stored separately
Secure area - access controlled
Decision taken on their fate
Returned goods
Destroyed unless suitable quality
SOP: decision regarding their fate (relabeling, resale, etc.)
– Consider: nature of product, special storage conditions,
condition, history, time elapsed since issue
Action taken to be recorded
20. 14.34 – 14.36
Materials
|
Module11 Slide20of25 2012
Reagents and culture media
Records for receipt or preparation
Reagents
Preparation in accordance with SOP
Appropriately labelled:
– concentration, standardization factor, shelf-life, date that
re-standardization is due, storage conditions
– signed and dated
Culture media
positive and negative controls each time prepared and used
Inoculum size appropriate
(See separate training module)
21. 14.37 – 14.40, 14.42
Materials
|
Module11 Slide21of25 2012
Reference standards - I
Official reference standards
Use preferable whenever these exist
Only for the purpose as per monograph
Storage conditions – see label
Reference standards prepared by the producer
Tested, released and stored in the same way as official
standards
In a secure area
A responsible person
Secondary or working standards
Appropriate checks and tests at regular intervals
Standardized against official reference standards – initially and
at regular intervals
22. 14.41, 14.43
Materials
|
Module11 Slide22of25 2012
Reference standards - II
Reference standards labelled with information including
Name of material
Batch, lot or control number
Date of preparation
Shelf-life
Potency
Storage conditions
Stored and used in an appropriate manner
23. 14.44 – 14.45
Materials
|
Module11 Slide23of25 2012
Waste materials
Waste materials
proper and safe storage when awaiting disposal
toxic substances and flammable materials:
– in suitably designed, separate, enclosed areas as per
national legislation
not to be allowed to accumulate
– collected in suitable containers for removal to collection
points
– safe and sanitary disposal
– regular and frequent intervals
25. Materials
|
Module11 Slide25of25 2012
Group session
List specific aspects of GMP requirements, in relation to the
groups of materials listed below, that you would assess when
inspecting a manufacturer
Printed packaging materials
Thermolabile materials
Water
Sterile materials
Identify three materials that present problems in your
experience
What are some of the problems that you have experienced
before and during inspection of materials?